Antoni Ribas
Founder & Member of Scientific Advisory BoardDr. Antoni Ribas, also known as Toni, M.D., Ph.D., has been a Member of Clinical Advisory Board at Inspirna, Inc. (formerly known as Rgenix, Inc.). since December 21, 2015. Dr. Ribas is Member of Scientific Advisory Council of Cancer Research Institute, Inc. He was Member of Scientific Advisory Board of RAPT Therapeutics, Inc. He is Scientific Advisor of Apricity Health, LLC. He is Chairman of Scientific Advisory Board at ImmPACT Bio USA Inc. Dr. Ribas serves as a Member of Scientific Advisory Board at Vault Nano Inc. He is Member of Scientific Advisory Board at Treadwell Therapeutics Inc. from February 2024. He is Member of Scientific Advisory Board of Dispatch Biotherapeutics, Inc. He is Founder and Chairman of the Board at Lutris Pharma Ltd from May, 2022 and has been its Director since its inception. He serves as Member of Scientific Advisory Board at Vial Health Technology Inc. He has been a Venture Partner at Ysios Capital Partners, SGEIC, S.A.U. since joining in June 2020. He served as Member of Scientific Advisory Board at Synthekine, Inc. since June 2021 until 2026. Dr. Ribas is an internationally recognized physician-scientist who conducts translational and clinical research aimed at understanding how the immune system can be used to treat cancer. He has been a leader in the research and clinical development of multiple types of therapeutic agents, including immune checkpoint inhibitors, gene-engineered T cells and BRAF-targeted therapies. His efforts have been instrumental in transforming the treatment paradigm for oncology patients, particularly those with malignant melanoma, having served as principal investigator for multiple trials, including those involving the breakthrough cancer therapy, Keytruda®. He is professor of medicine at the David Geffen School of Medicine at UCLADr. Perlman also served as President of Vitesse Biologics. He is also Managing Director and Chief Medical Officer of Velocity Pharmaceutical Development. He is Founder of Tango Therapeutics, Inc. and serves as its Member of Scientific Advisory Board since 2021. He supports the evaluation of potential investments and advise the team with respect to investment decisions. He is a world expert in immuno-oncology. He was the President of the American Association for Cancer Research (AACR) from 2020 to 2021. He had been Member of Scientific Advisory Board at Merus N.V. since August 22, 2018 until 2025. Dr. Ribas has been an Independent Director of Arcus Biosciences, Inc. since October 2019 and its Member of Scientific Advisory Board since 2015. He was a Member of Clinical Advisory Board at Arcus Biosciences, Inc. He serves as the Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC). Dr. Ribas serves as Director of the Cell and Gene Therapy Core Facility and Training Faculty at the Broad Stem Cell Research Center at UCLA. He serves as Member of Scientific Advisory Board at Appia Bio, Inc. He serves as Director of the Cell and Gene Therapy Core Facility at the University of California, Los Angeles. He serves as a consultant for numerous clinical development drug programs for major companies like Amgen, Bristol-Myers Squibb, Genentech, GSK, Millennium, Novartis, Pfizer, Plexxikon, Roche and serves as a SAB Member at Kite pharma, Compugen and Flexus-Bio. Dr. Ribas is a Specialist in tumor immunology and cancer vaccine development and clinical trials in immunotherapy. He served as an Associate Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center. Dr. Ribas served as Senior Vice President of Clinical Research and Development at Kite Pharma, Inc. He founded or advised several successful biopharma companies in addition to Arcus, such as Kite Pharma and Flexus Biosciences. He has been a Member of the Scientific Advisory Board at Immunovative Therapies Ltd. since September 2012. He serves as a Member of Scientific Advisory Board of IsoPlexis Corp. He has been a Member of Scientific Advisory Board at Compugen Ltd. since August 2013. He had been a Member of Scientific Advisory Board at Five Prime Therapeutics, Inc. since January 05, 2016 until 2019. He serves as a Member of Scientific Advisory Board at RAPT Therapeutics, Inc. (formerly known as FLX Bio. Inc.), Advaxis, Inc. and cCAM Biotherapeutics Ltd. He was a Member of Scientific Advisory Board at CytomX Therapeutics, Inc. He served as a Member of Scientific Advisory Board at MannKind Corporation and Kite Pharma, Inc. He serves as the President of the American Association of Immunologists. He co-founded PACT Pharma. Dr. Allison is a Member of the National Academy of Sciences and the Institute of Medicine. He is an elected Member of the American Society of Clinical Investigation (ASCI). He is Professor of Medicine, Professor of Surgery and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA) since July 2011. Dr. Ribas was an Associate Professor of Medicine and Surgery at UCLA. He is a Director of the Parker Institute for Cancer Immunotherapy Center at UCLA since 2016. Dr. Ribas is a leading Investigator in the clinical development of multiple new agents for melanoma, including tremelimumab(anti-CTLA4 antibody), PLX4032 (BRAF inhibitor) GSKI 120212 (Mek inhibitor), TAK-733 (Mek inhibitor) MKC1106-MT (melanoma vaccine), nabpaclitaxel and CALAA-01 (nanoparticle-siRNA,). He is Vice-President of the Society for Melanoma Research (SMR). He is a recognized expert and key opinion leader in the treatment of patients with advanced melanoma and tumor immunotherapy having published over 200 manuscripts and book chapters in this field. He is a Physician-Scientist who conducts laboratory and clinical research in malignant melanoma, focusing on BRAF-targeted therapies and immunotherapy with T cell receptor (TCR) adoptive cell transfer and checkpoint inhibitors. These studies have been published in numerous journals including the New England Journal of Medicine, Nature, Nature Medicine, Cancer Discovery, the Proceedings of the National Academy of Sciences (PNAS) and others. He has received numerous awards, including the Centeon Award for Innovative Breakthroughs in Immunology and the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology. He received AAI-Dana Award in Human Immunology Research and the C. Chester Stock Award for Distinguished Achievement in Biomedical Research. Following a fellowship in hematology/oncology in the Department of Medicine at UCLA, he has held numerous faculty and administrative positions at UCLA since 2001. He is a Fellow of the American Academy of Microbiology and the American Association for the Advancement of Science. Dr. Ribas has received a myriad of awards and honors, including the AACR-CRI Lloyd J. Old Award in Cancer Immunology, the AACR Richard and Hinda Rosenthal Award and the National Cancer Institute (NCI) Outstanding Investigator Award. Dr. Ribas has also served on the Board of Directo
Positions
- Company NameTango Therapeutics, Inc.Stock CodeTNGXPositionFounder & Member of Scientific Advisory BoardColleagues
- MPMalte PetersPresident, CEO & Director
- RWRobert William AzelbyIndependent Chairman of the Board
- BLBarbara L. WeberExecutive Officer
- ASAdam S. CrystalPresident of Research & Development
- AAAlan AshworthFounder & Member of Scientific Advisory Board
- WGWilliam G. KaelinFounder & Member of Scientific Advisory Board
